Advertisement

Clinical Drug Investigation

, Volume 39, Issue 12, pp 1175–1184 | Cite as

Investigation of the Association Between Total and Free Plasma and Saliva Mycophenolic Acid Concentrations Following Administration of Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients

  • Emily BrooksEmail author
  • Susan E. Tett
  • Nicole M. Isbel
  • Brett McWhinney
  • Christine E. Staatz
Original Research Article
  • 59 Downloads

Abstract

Background and Objectives

Mycophenolic acid (MPA) is commonly used following renal transplant. Saliva MPA concentrations may reflect the pharmacologically active form of MPA in plasma. Therapeutic drug monitoring using saliva is convenient and non-invasive. This study examined the correlation between total and free plasma and saliva MPA concentrations following enteric-coated mycophenolate sodium (EC-MS) administration in renal transplant recipients.

Methods

Total and free plasma and saliva MPA concentrations were measured simultaneously in 20 adult renal transplant recipients 1–2 months’ post-transplant. Thirteen samples were taken pre-dose and at specified time points up until 12 h post-dose.

Results

When considering all time points, correlation between total plasma and saliva MPA was r2 = 0.51 and between free plasma and saliva MPA concentrations r2 = 0.41. The correlation between total plasma MPA area under the concentration–time curve (AUC) or free plasma AUC and saliva MPA AUC was r2 = 0.25 and r2 = 0.13, respectively. The correlation between total plasma MPA AUC and total plasma MPA trough (C0) concentrations was r2 = 0.51, and between total plasma MPA AUC and saliva MPA trough concentrations, r2 = 0.03.

Conclusions

Measurement of MPA concentration in saliva cannot currently replace plasma measurement for therapeutic drug monitoring of MPA following EC-MS administration. Additional studies are required to examine the relationship between MPA saliva concentrations and patient outcomes.

Notes

Acknowledgements

The authors would like to thank the Princess Alexandra Hospital Department of Nephrology medical and nursing staff for their assistance with the study, the patients for their involvement in the study and the reviewers for their helpful comments.

Author contributions

Emily Brooks performed a literature review, designed the study, collected and analysed the data and wrote the manuscript first draft. Susan Tett assisted in literature review, study design and manuscript review. Nicole Isbel assisted in study design, patient recruitment, data collection and manuscript review. Brett McWhinney analysed the samples and assisted with manuscript review. Christine Staatz assisted in literature review, data analysis, study design and manuscript review.

Compliance and Ethical Standards

Funding

No sources of funding were used to assist with the preparation of this review. Dr. Brooks was a student; Drs. Tett, Staatz and Isbel receive salaries from university/hospital sources.

Conflict of interest

Dr. Emily Brooks: none to declare. Associate Prof. Christine Staatz: none to declare. Prof. Susan Tett: none to declare. Associate Prof. Nicole Isbel: none to declare. Mr Brett McWhinney: none to declare.

Ethics approval

All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments). The University of Queensland and Princess Alexandra Hospital Ethics Committees approved the study (Approval numbers: 2013000718, HREC/12/QPAH/538).

Informed consent

All patients provided informed written consent.

References

  1. 1.
    Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transpl Rev. 2011;25:47–57.CrossRefGoogle Scholar
  2. 2.
    Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88:1351–89.CrossRefGoogle Scholar
  3. 3.
    Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58.CrossRefGoogle Scholar
  4. 4.
    Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5:341–58.CrossRefGoogle Scholar
  5. 5.
    van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80:S244–53.CrossRefGoogle Scholar
  6. 6.
    Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497–504.PubMedGoogle Scholar
  7. 7.
    Dasgupta A. Therapeutic drug monitoring of mycophenolic acid. Adv Clin Chem. 2016;76:165–84.CrossRefGoogle Scholar
  8. 8.
    Mudge DW, Atcheson BA, Taylor PJ, et al. Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit. 2004;26:453–5.CrossRefGoogle Scholar
  9. 9.
    Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759–68.CrossRefGoogle Scholar
  10. 10.
    Langman LJ. The use of oral fluid for therapeutic drug management: clinical and forensic toxicology. Ann N Y Acad Sci. 2007;1098:145–66.CrossRefGoogle Scholar
  11. 11.
    Wiesen MH, Farowski F, Feldkötter M. Liquid chromatography–tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. J Chromatogr A. 2012;1241:52–9.CrossRefGoogle Scholar
  12. 12.
    Shen B, Li S, Zhang Y, et al. Determination of total, free and saliva mycophenolic acid with a LC–MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed. 2009;50:515–21.CrossRefGoogle Scholar
  13. 13.
    Pichini S, Altieri I, Zuccaro P, et al. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet. 1996;30:211–28.CrossRefGoogle Scholar
  14. 14.
    Choo E, Huestis M. Oral fluid as a diagnostic tool. Clin Chem Lab Med. 2004;42:1273–87.CrossRefGoogle Scholar
  15. 15.
    Jonge HNM, Kuypers D. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009;31:416–35.CrossRefGoogle Scholar
  16. 16.
    Mendoza AE, Gohh RY, Akhlaghi F. Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. Ther Drug Monit. 2006;28:402–6.CrossRefGoogle Scholar
  17. 17.
    Delavenne X, Juthier L, Pons B, et al. UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: application to pharmacokinetic study. Clin Chim Acta. 2011;412:59–65.CrossRefGoogle Scholar
  18. 18.
    Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503–12.CrossRefGoogle Scholar
  19. 19.
    Gallardo E, Barroso M, Queiroz JA. Current technologies and considerations for drug bioanalysis in oral fluid. Bioanlaysis. 2009;1:637–67.CrossRefGoogle Scholar
  20. 20.
    Aps JK, Martens LC. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int. 2005;150:119–31.CrossRefGoogle Scholar
  21. 21.
    Groschl M, Kohler H, Topf HG. Evaluation of saliva collection devices for the analysis of steroids, peptides and therapeutic drugs. J Pharm Biomed. 2008;47:478–86.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.School of MedicineThe University of QueenslandBrisbaneAustralia
  2. 2.School of PharmacyThe University of QueenslandBrisbaneAustralia
  3. 3.Department of NephrologyThe Princess Alexandra HospitalBrisbaneAustralia
  4. 4.Pathology QueenslandRoyal Brisbane and Women’s HospitalBrisbaneAustralia

Personalised recommendations